CAMBRIDGE, Mass. and TAIPEI, June 10, 2026
Elixiron Immunotherapeutics announced positive interim results from its ongoing Phase 2 proof-of-concept study evaluating enrupatinib (EI-1071), an investigational oral CSF-1R inhibitor designed to reduce neuroinflammation in patients with Alzheimer’s disease (AD). The study demonstrated a favorable safety profile, evidence of neuroinflammation reduction through advanced brain imaging, and early signs of cognitive improvement in selected patients. The findings provide support for a precision medicine approach targeting neuroinflammation as a potential disease-modifying strategy for Alzheimer’s disease.
Enrupatinib Demonstrates Neuroinflammation Reduction and Target Engagement
The interim analysis showed strong evidence that enrupatinib successfully engages its intended target and modulates neuroinflammatory activity in the brain. Among biomarker-selected participants, 80% (4 of 5 patients) achieved an average reduction of more than 30% in TSPO-PET imaging signals, a recognized marker of neuroinflammation. Significant reductions were observed in the Posterior Cingulate and Precuneus, brain regions closely associated with Alzheimer’s disease progression. In the broader evaluable patient population, 57% of participants demonstrated reductions in neuroinflammatory activity after 28 days of treatment, providing direct in vivo evidence that enrupatinib may effectively suppress disease-associated inflammation driven by activated microglia.
Early Cognitive Improvements Support Disease-Modifying Potential
In addition to biomarker improvements, researchers observed encouraging preliminary signs of clinical benefit. One participant who responded strongly on TSPO-PET imaging demonstrated substantial improvement across multiple exploratory cognitive and functional assessments, including an 8-point increase in Mini-Mental State Examination (MMSE) score from baseline. While the trial was not designed to formally assess cognitive efficacy at this stage, the observation suggests that reducing neuroinflammation may potentially translate into meaningful improvements in cognitive function. These findings strengthen the scientific rationale for targeting inflammatory pathways that contribute to amyloid and tau pathology in Alzheimer’s disease.
Advertisement
Favorable Safety Profile Supports Continued Clinical Development
The study reported a favorable safety and tolerability profile, with no drug-related serious adverse events observed among evaluable participants. Importantly, investigators reported no clinically significant hepatotoxicity, a concern that has affected earlier compounds within the CSF-1R inhibitor class. The clean safety profile supports the potential for chronic administration, which is essential for therapies intended to treat progressive neurodegenerative diseases. Researchers believe this safety advantage may differentiate enrupatinib from previous attempts to target neuroinflammation in Alzheimer’s disease.
Precision Medicine Strategy Advances Toward Controlled Trials
A key finding from the interim analysis was the identification of a potential predictive biomarker associated with treatment response. If validated in future studies, the biomarker could help identify patients most likely to benefit from therapy, enabling a more efficient precision medicine approach to Alzheimer’s treatment. Based on these encouraging results, Elixiron plans to launch a larger placebo-controlled clinical trial enriched with biomarker-selected patients to further evaluate enrupatinib’s efficacy and confirm its therapeutic potential as a disease-modifying treatment for Alzheimer’s disease.
Source: Elixiron Immunotherapeutics press release
